| Literature DB >> 30937377 |
Kevin T Bennett1, Sharon E Bone1, Andrew C Akin1, Eva R Birnbaum1, Anastasia V Blake1,2, Mark Brugh1, Scott R Daly2, Jonathan W Engle1,3, Michael E Fassbender1, Maryline G Ferrier1, Stosh A Kozimor1, Laura M Lilley1, Christopher A Martinez1, Veronika Mocko1, Francois M Nortier1, Benjamin W Stein1, Sara L Thiemann1, Christiaan Vermeulen1.
Abstract
Radionuclides find widespread use in medical technologies for treating and diagnosing disease. Among successful and emerging radiotherapeutics, 119Sb has unique potential in targeted therapeutic applications for low-energy electron-emitting isotopes. Unfortunately, developing 119Sb-based drugs has been slow in comparison to other radionuclides, primarily due to limited accessibility. Herein is a production method that overcomes this challenge and expands the available time for large-scale distribution and use. Our approach exploits high flux and fluence from high-energy proton sources to produce longer lived 119mTe. This parent isotope slowly decays to 119Sb, which in turn provides access to 119Sb for longer time periods (in comparison to direct 119Sb production routes). We contribute the target design, irradiation conditions, and a rapid procedure for isolating the 119mTe/119Sb pair. To guide process development and to understand why the procedure was successful, we characterized the Te/Sb separation using Te and Sb K-edge X-ray absorption spectroscopy. The procedure provides low-volume aqueous solutions that have high 119mTe-and consequently 119Sb-specific activity in a chemically pure form. This procedure has been demonstrated at large-scale (production-sized, Ci quantities), and the product has potential to meet stringent Food and Drug Administration requirements for a 119mTe/119Sb active pharmaceutical ingredient.Entities:
Year: 2019 PMID: 30937377 PMCID: PMC6439462 DOI: 10.1021/acscentsci.8b00869
Source DB: PubMed Journal: ACS Cent Sci ISSN: 2374-7943 Impact factor: 14.553
Figure 1Plot showing how 119Sb isolated from the 119mTe parent (red and green traces) generated at a high-energy proton source prolongs access time to 119Sb directly produced from 119Sn (blue trace) at a common cyclotron.
Figure 2Dependence of the inflection point energies on acid concentration from solution phase Sb (top) and Te (bottom) K-edge XANES measurements in HF (red) and HCl (blue) solutions. Measurements from Sb and Te standards and Te that has been loaded onto various resins (anion, Rare Earth, and CL) are shown in black. Uncertainties were estimated at 0.2 eV for Te and 0.7 eV for Sb based on our ability to reproduce these values.
Figure 3Normalized Sb (left) and Te (right) K-edge XANES from aqueous solutions (black traces; top—HCl, 0–12 M; bottom—HF, 0.01–28 M) as well as for Te fixed to the CL (red trace), anion (blue trace), and Rare Earth (green trace) resins. The SbCl3, Sb2O5, Te metal, TeO2, and Te(OH)6 oxidation state references are shown as gray traces.
Figure 4Sb and Te K-edge EXAFS (a) and Fourier transform–EXAFS (b) from aqueous solutions (HCl, 0–12 M) as well as from Te fixed to the anion and Rare Earth resins. Experimental spectra are shown in black and fits in red. (c) Graphical representation showing the O (blue ●), Cl (red ●), and the total (○) coordination numbers dependence on HCl concentrations for Sb (left) and Te (right).
Fitting Parameters for Sb in Solution with 2–12 M HCl
| Sb–Cl | ||||
|---|---|---|---|---|
| sample | CN | σ2 (Å2) | ||
| 2 M HCl | 0.95 | 1.0 ± 0.4 | 2.37 ± 0.018 | 0.0033 |
| 4 M HCl | 0.95 | 2.4 ± 0.3 | 2.39 ± 0.014 | 0.0033 |
| 6 M HCl | 0.95 | 3.7 ± 0.2 | 2.38 ± 0.008 | 0.0033 |
| 8 M HCl | 0.95 | 4.8 ± 0.5 | 2.37 ± 0.008 | 0.0034 ± 0.0010 |
| 10 M HCl | 0.95 | 5.7 ± 0.3 | 2.37 ± 0.005 | 0.0040 ± 0.0006 |
| 12 M HCl | 0.95 ± 0.06 | 5.8 ± 0.4 | 2.37 ± 0.005 | 0.0033 ± 0.0006 |
The amplitude reduction factor was set to 0.95 based on previously reported values (0.95 ± 0.05) for Sb2O5.[46]
The Sb–Cl Debye–Waller factor was constrained based on fits to the 12 M HCl EXAFS spectrum.
The Sb–O Debye–Waller factor was constrained based on fits to the 2 M HCl EXAFS spectrum.
Fitting Parameters for Te in Solution with 0–12 M HCl
| Te–Cl | ||||
|---|---|---|---|---|
| sample | CN | σ2 (Å2) | ||
| 0 M HCl | 0.9 | |||
| 2 M HCl | 0.9 | |||
| 4 M HCl | 0.9 | 2.3 ± 0.5 | 2.49 ± 0.02 | 0.0058 ± 0.0025 |
| 6 M HCl | 0.9 | 3.7 ± 0.5 | 2.49 ± 0.01 | 0.0067 ± 0.0017 |
| 8 M HCl | 0.9 | 4.0 ± 0.4 | 2.49 ± 0.010 | 0.0075 ± 0.0013 |
| 10 M HCl | 0.9 | 4.6 ± 0.5 | 2.48 ± 0.011 | 0.0097 ± 0.0014 |
| 12 M HCl | 0.9 | 4.5 ± 0.4 | 2.46 ± 0.011 | 0.0098 ± 0.0013 |
| Rare Earth | 0.9 | 4.8 ± 0.3 | 2.51 ± 0.005 | 0.0074 ± 0.0007 |
| Anion | 0.9 | 4.3 ± 0.3 | 2.51 ± 0.006 | 0.0050 ± 0.0008 |
Amplitude reduction factor set based on ref (47).
Debye–Waller factor set based on fits of EXAFS spectrum for Te in 2 M HCl.
Scheme 1Diagram Showing the Average Sb and Te Stoichiometries for Species Present between 0 and 12 M HCl
Scheme 2Overall Separation Scheme for 119mTe from an natSb Target
Figure 5Chromatograms from the Te/Sb separations utilizing CL, Rare Earth, and anion-exchange resins. (left) Separation of 121Te (3240 cps) from stable Sb (160 mg) traced with 124Sb (114.5 cps) using a Bio-Rad column (10 mL column) containing CL resin (Eichrom Technologies; 1.5 mL; 100–150 μm). (middle) Separation of stable Sb (12 mg), 124Sb (32 cps), and 121mTe (260 cps) using a Bio-Rad column (10 mL column) containing Rare Earth resin (Eichrom Technologies; 1.5 mL; 50–100 μm). (right) Separation of stable Sb (12 mg), 124Sb (32 cps), and 121mTe (260 cps) using a Bio-Rad column (10 mL) containing AG 1-X8 anion-exchange resin (Bio-Rad; 1.7 mL; 100–200 mesh).